Stabilization of vision and reduction in inflammatory factors are early intervention goals.<\/li>\n<\/ul>\nDENVER \u2014 Experts agreed that there is a significant unmet need for early intervention in diabetic macular edema, according to a presentation at the Association for Research in Vision and Ophthalmology meeting.<\/p>\n
\u201cWe know that DME is a leading cause of vision loss in working-age adults, but many patients are left untreated,\u201d Baruch D. <\/b>Kuppermann<\/b>, MD, PhD,<\/b> told Healio. \u201cThis is somewhat surprising, but at 1 year after diagnosis of DME, 60% of patients are left untreated.\u201d<\/p>\n
Kuppermann and colleagues designed the DME AWARE Delphi study to better understand and build consensus around the management of DME. Over the course of three surveys, the researchers proposed 284 statements to a group of 20 experts, consisting of mainly retina specialists and some anterior segment surgeons, according to Kuppermann.<\/p>\n
Through administration of the surveys, the researchers were able to pare down the proposed statements to a few consensus findings on unmet needs in DME, including:<\/p>\n
\nnoninvasive treatment;<\/li>\n improved treatment adherence;<\/li>\n options for early intervention;<\/li>\n therapies for concomitant use with standard of care; and<\/li>\n improved treatment safety and tolerability in early DME.<\/li>\n<\/ul>\nKupperman said the researchers also identified two early intervention goals in DME: improvement or stabilization of vision as well as reduction in inflammatory factors. The experts defined early detection as \u201cdetection of DME prior to presence of fluid\u201d and early intervention as \u201ctreatment of DME prior to functional deterioration,\u201d according to the study.<\/p>\n
When it comes to early intervention in DME, \u201cthe consensus was the diagnosis was at least one line loss of BCVA from 20\/20, and there was strong consensus on intervening if it was noninvasive, but there was lack of consensus if it was intravitreal,\u201d Kuppermann said. \u201cHowever, when we went to two line loss, there\u2019s even stronger interest in intervening with noninvasive therapy, but there was somewhat more interest in intervening with intravitreal therapy if it was two line loss.\u201d<\/p>\n
For more information:<\/h2>\n Baruch D. Kuppermann, MD, PhD,<\/b> director of the Gavin Herbert Eye Institute at the University of California, Irvine, can be reached at bdkupper@uci.edu.<\/p>\n\n
\n
Published by:<\/span>\n
Sources\/Disclosures<\/h3>\n Source: <\/h2>\n Kuppermann BD, et al. Unmet needs in DME management: Latest findings from the DME AWARE Delphi study. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver.<\/p>\n
\n
Disclosures: <\/strong>
<\/p>\n
\n
\n
<\/p>\n
Ask a clinical question<\/strong> and tap into Healio AI’s knowledge<\/strong> base.<\/p>\n
<\/p>\nPubMed, enrolling\/recruiting trials, guidelines<\/li>\n
<\/p>\n
Clinical Guidance, Healio CME, FDA news<\/li>\n
<\/p>\n
Healio’s exclusive daily news coverage of clinical data<\/li>\n
\n <\/ul>\n
Learn more<\/button>\n <\/div>\n<\/div>\n
![\"occular](\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/osn.svg?la=en&h=32&w=145&hash=C099A5ADC410818ECDF2097A4CD3C51F\")
\n <\/div>\n<\/p><\/div>\n<\/p><\/div>\n